What is Nuvalent?
Nuvalent is a clinical-stage biopharmaceutical company dedicated to advancing precision medicine for patients battling challenging cancers, particularly non-small-cell lung cancer (NSCLC). The company's core strategy involves developing highly selective kinase inhibitors designed to overcome treatment resistance and improve patient outcomes. Nuvalent's lead programs are engineered to target specific genetic mutations that fuel tumor growth, offering a more personalized and effective therapeutic option. Founded in 2017 and headquartered in Cambridge, Massachusetts, Nuvalent is positioned at the forefront of oncology innovation, leveraging cutting-edge science to address unmet medical needs in a critical disease area.
How much funding has Nuvalent raised?
Nuvalent has raised a total of $351M across 3 funding rounds:
Multiple Rounds
$351M
Series A (2021): $50M with participation from Deerfield Communications Inc
Series B (2021): $135M led by Deerfield, Wellington Management, Boxer Capital, Viking Global Investors, Fidelity Management and Research, Avoro Capital, Logos Capital, Fairmount Funds Management, Bain Capital Life Sciences, Driehaus Capital Management, and Janus Henderson Investors
Share Placement (2021): $166M, investors not publicly disclosed
Key Investors in Nuvalent
Deerfield
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
Wellington Management
Wellington Management Company, LLP is a global, independent investment management firm based in Boston, Massachusetts. It provides institutional clients with portfolio management, research, and tailored investment solutions across equities, fixed income, multi-asset, and alternative strategies.
Boxer Capital
Boxer Capital, LLC, is a private investment fund. It invests in biotechnology drug development across multiple therapeutic indications. The company has a concentrated portfolio of public and private companies. Boxer Capital is based in San Diego, California.
What's next for Nuvalent?
With substantial enterprise-level backing and a recent strategic investment, Nuvalent is poised for a significant growth phase. The capital infusion is anticipated to fuel the advancement of its lead drug candidates through clinical trials, potentially paving the way for regulatory submissions and market entry. This strategic financing will likely bolster the company's research and development capabilities, expand its operational infrastructure, and support its mission to deliver life-changing precision therapies. Nuvalent's focus on overcoming resistance mechanisms in NSCLC positions it as a key player in the evolving landscape of targeted cancer treatments, with future developments expected to be closely watched by the biotech and investment communities.
See full Nuvalent company page
